TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a DHODH inhibitor or an antimetabolite. Methods are provided forpredicting the sensitivity of tumor cell growth to inhibition by a DHODH inhibitor or an antimetabol...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
23.10.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with a DHODH inhibitor or an antimetabolite. Methods are provided forpredicting the sensitivity of tumor cell growth to inhibition by a DHODH inhibitor or an antimetabolite, comprising assessing whether the tumor cell comprises a mutant IDH gene or protein whereby cells that comprise a mutant IDH gene or protein are sensitive to inhibition by DHODH inhibitors and antimetabolites.
本发明提供用于预测用DHODH抑制剂或抗代谢物治疗癌症患者的有效性的诊断和预后方法。提供了用于预测肿瘤细胞生长对DHODH抑制剂或抗代谢物引起的抑制的敏感性的方法,包括评估肿瘤细胞是否包含突变型IDH基因或蛋白,从而包含该突变型IDH基因或蛋白的细胞对DHODH抑制剂和抗代谢物的引起的抑制是敏感的。 |
---|---|
Bibliography: | Application Number: CN201680077339 |